Pharma giant Bristol-Myers Squibb has elected Dinesh Paliwal to its Board of Directors to serve as a member of the Committee on Directors and Corporate Governance.
Paliwal is the chairman, president and CEO of Harman International Industries and, according to BMS’ CEO Lamberto Andreotti, is “an accomplished leader who has worked in senior positions in Asia, Europe and the United States.”
The firm last week teamed up with CMO Simcere in order to develop and market its arthritis biologic drug Orencia in China.
Orencia is, at present, manufactured from the firm’s Devens facility in Massachusetts, US – a facility that received a boost in April with a $250m expansion.
Next up and Shire’s ex-CEO Angus Russell has been appointed to the Board of Directors at Questcor Pharmaceuticals.
He served five years at Shire – who has recently been investing in ophthalmology acquisitions - in the top position, and nine years more as CFO, retiring at the end of April this year.
“Over his many years at Shire, Angus spearheaded and achieved numerous initiatives and helped to transform the company into the global industry leader that it is today,” said Questcor’s Chairman Virgil Thompson.
News from miRagen Therapeutics now, and the biopharmaceutical firm has made two new appointments:
Christoper Mori – who has previously worked for Ambit, GSK and Agensys – has joined the firm as Chief Business Officer.
Dr. Aimee Jackson will serve as Director of Target Development. Jackson has over ten years of experience in the industry and previously worked for Rosetta Inpharmatics/Merck in Seattle.
“The additions of Chris and Aimee strengthen our management team and further facilitate our ability to develop promising microRNA-targeting therapeutic candidates,” said Dr. William Marshall, President and CEO of mirage.
And finally this week, KaloBios Pharmaceuticals has appointed Donald Joseph as its new Chief Legal Officer.
Having served as general counsel corporate secretary and in other senior management roles at biopharmaceutical companies, including Abgenix and Renovis, Joseph’s “primary therapeutic areas of experience, which include oncology, infectious diseases, and antibody technology, are directly relevant to KaloBios' own pipeline of patient-targeted, first-in-class monoclonal antibodies,” according to David Pritchard, CEO.